Micro-Energy Medical Completes Tens of Millions RMB Series A Financing to Accelerate Product Development and Global Expansion

Recently, Micro-Energy Medical Technology Co., Ltd. (hereinafter referred to as "Micro-Energy Medical") announced the completion of a multi-million yuan Series A round of financing. This round of financing will undoubtedly inject strong momentum into its product development, clinical applications, and global layout, facilitating innovative breakthroughs.

Micro-Energy Medical Technology Co., Ltd. was founded in 2021 as an innovative medical technology company focusing on active energy endovascular interventional devices. The company is dedicated to the research and development of innovative medical devices with a global perspective, building its product portfolio around precise interventional treatments for varicose veins, coronary heart disease, and peripheral vascular diseases, while promoting the application of cutting-edge laser technology in the field of vascular intervention. The core team, composed of senior experts from China and Germany, has extensive multidisciplinary R&D experience. With international strategic planning and business promotion capabilities, the team is committed to providing advanced medical solutions to customers worldwide.

In product planning, Micro-Energy Medical focuses on key indications with significant clinical needs, aiming to build a portfolio of "first-in-China" and "world-leading" active energy vascular intervention products. This includes four core product lines: the 355nm solid-state pulsed laser vascular ablation system, the differentiated innovative shock wave balloon system, the 1470nm & 1940nm laser ablation system, and the laser renal artery sympathetic denervation system (RDN). The products cover a wide range of vascular fields with many patients, such as coronary arteries and peripheral arteries and veins, while rapidly expanding indications for both internal and external clinical applications.

Currently, SurgiLight® 1470 – the first domestically produced 1470nm wavelength radial fiber intravenous laser ablation system with independent intellectual property rights in China – has obtained registration certificates both in China and internationally and has been officially launched in the market, receiving unanimous praise from medical institutions and clinical experts. Other product lines are also proceeding as planned, with clinical trials progressing steadily.

At the same time, Micro-Energy Medical boasts a diversified background and international market positioning, with leading product technology and minimal market substitution. Therefore, in recent years, it has attracted strong interest and favor from overseas markets. According to reports, under the active promotion of the international sales team, Micro-Energy products have now been registered and are being sold in major vascular interventional surgery markets such as the United States, Mexico, Brazil, Indonesia, Vietnam, and India. Market deployment is steadily progressing in the European Union, Saudi Arabia, and the United Arab Emirates, with sales expected to officially commence in 2026.

Mr. Wang Gang, CEO of Micro-Energy Medical, stated: "We will intensify our efforts to bring more innovative medical products to the market as soon as possible, safeguarding global vascular health with technological power. Micro-Energy Medical will further increase investment in the development of active energy endovascular interventional product portfolios and new technologies, accelerate the industrialization and global expansion of existing innovative products, and move steadily towards our vision of becoming a global leader in vascular health protection."